• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: OGDEN MANUFACTURING PLANT OPTIFLUX 160NRE DIALYZER FINISHED ASSY. DIALYZER, HIGH PERMEABILITY WITH OR WITHOUT SEALED DIALYSATE SYSTEM

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

OGDEN MANUFACTURING PLANT OPTIFLUX 160NRE DIALYZER FINISHED ASSY. DIALYZER, HIGH PERMEABILITY WITH OR WITHOUT SEALED DIALYSATE SYSTEM Back to Search Results
Model Number 0500316E
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problems Itching Sensation (1943); Swelling (2091); Dizziness (2194); Reaction (2414); Diaphoresis (2452); Chest Tightness/Pressure (2463)
Event Date 05/19/2020
Event Type  Injury  
Manufacturer Narrative
Clinical review: based on the available information, there is a temporal and a likely causal relationship between the fresenius optiflux 160nre dialyzer and the patient¿s reaction (characterized by dizziness, chest tightness, itching, with face and neck red, ears and tongue swollen, difficulty speaking, and sweating during the hd treatment). Although rare, hypersensitivity or anaphylactoid reactions to optiflux dialyzers are a known risk during hemodialysis. There is no evidence of an optiflux 160nre dialyzer product deficiency or malfunction. Additionally, although the patient experienced an adverse reaction during treatment, there is no allegation of a product malfunction or deficiency related to this event. The plant investigation is in process. A supplemental mdr will be submitted upon completion of this activity.  .
 
Event Description
A voluntary medwatch report was received from a hemodialysis (hd) clinic manager reporting a patient adverse event. A hemodialysis (hd) patient arrived for a regularly scheduled treatment on (b)(6) 2020. This patient received dialysis three times per week with a three hour and thirty-minute treatment. The patient¿s pre-vital signs were as follows: blood pressure (bp)147/76, pulse 79, temperature 96. 8. At approximately 0925 hours dialysis was initiated via an arteriovenous fistula (avf) (location not provided) utilizing the optiflux 160nre dialyzer which the patient had been using without incident since hd initiation. Within approximately 5-10 minutes into the treatment the patient complained of feeling dizzy, chest tightness and itching, as well as displaying a red face and neck, and swollen ears and tongue. In addition, the patient had difficulty speaking and was sweating. Vital signs were recorded at the time as bp 109/67 and pulse 121. Treatment was terminated at this time and the patient was administered oxygen via nasal cannula at 3l/min. The patient was also administered 400ml of normal saline (ns). At 0935 hours 911 was called and 25mg oral benadryl was administered. Emergency medical services (ems) arrived and in route to the emergency room (er) the patient was given an intramuscular (im) injection of 0. 3mg epinephrine (epi). Once at the er, the patient received 50mg intravenous (iv) benadryl, 0. 3mg im epi, 20mg iv famotidine and 25mg iv solumedrol. The patient was admitted to the intensive care unit (icu) for close monitoring with orders for iv benadryl as needed and scheduled famotidine twice a day (dose not provided). The patient recovered and was discharged from the hospital on (b)(6) 2020 and returned to hd therapy on (b)(6) 2020. The optiflux 160nre was marked as an allergy and the patient was switched to the nipro cellentia 17h dialyzer.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand NameOPTIFLUX 160NRE DIALYZER FINISHED ASSY.
Type of DeviceDIALYZER, HIGH PERMEABILITY WITH OR WITHOUT SEALED DIALYSATE SYSTEM
Manufacturer (Section D)
OGDEN MANUFACTURING PLANT
director, site quality
475 west 13th street
ogden UT 84404
Manufacturer (Section G)
OGDEN MANUFACTURING PLANT
director, site quality
475 west 13th street
ogden UT 84404
Manufacturer Contact
matthew amaral
920 winter st
waltham, MA 02451
7816999758
MDR Report Key10129152
MDR Text Key195169065
Report Number1713747-2020-00225
Device Sequence Number1
Product Code KDI
Combination Product (y/n)N
Reporter Country CodeUS
PMA/PMN Number
K002761
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type company representative,health
Reporter Occupation
Type of Report Initial,Followup
Report Date 07/06/2020
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received06/08/2020
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator
Device Model Number0500316E
Device Catalogue Number0500316E
Device Lot Number20AU01001
Was Device Available for Evaluation? Device Returned to Manufacturer
Date Returned to Manufacturer06/12/2020
Is the Reporter a Health Professional? Yes
Was the Report Sent to FDA?
Device AgeMO
Event Location No Information
Date Manufacturer Received06/30/2020
Was Device Evaluated by Manufacturer? Yes
Date Device Manufactured01/04/2020
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial

Patient Treatment Data
Date Received: 06/08/2020 Patient Sequence Number: 1
-
-